Recursion Pharmaceuticals

Recursion Pharmaceuticals ROA

The Return on Assets (ROA) of Recursion Pharmaceuticals (RXRX) as of Nov 16, 2026 is -43.74 %. In the previous year, Return on Assets (ROA) was -32.01 % — a change of 36.65% (lower).

ROA

-43.74 %

YoY

36.65%

Last updated:

In 2025, Recursion Pharmaceuticals's return on assets (ROA) was -43.74 %, a 36.65% increase from the -32.01 % ROA in the previous year.

The Recursion Pharmaceuticals ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-61.64 USD
Jan 1, 2020
-29.14 USD
Jan 1, 2021
-29.18 USD
Jan 1, 2022
-34.14 USD
Jan 1, 2023
-50.19 USD
Jan 1, 2024
-32.01 USD
Jan 1, 2025
-43.74 USD
The Recursion Pharmaceuticals ROA history
YEARROAYoY
-43.74 %+36.65%
-32.01 %-36.22%
-50.19 %+47.00%
-34.14 %+17.01%
-29.18 %+0.13%
-29.14 %-52.73%
-61.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

ROA Details

Understanding Recursion Pharmaceuticals's Return on Assets (ROA)

Recursion Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Recursion Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Recursion Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Recursion Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Return on Assets (ROA) of Recursion Pharmaceuticals is -43.74 % in 2025.

Return on Assets (ROA) of Recursion Pharmaceuticals changed from -32.01 % to -43.74 %, representing a 36.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Recursion Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals